Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Index
RUT
Market Cap
670.46M
Enterprise Value
464.36M
Income
-74.09M
Sales
0.00M
Book/sh
3.17
Cash/sh
3.26
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
124
IPO
Mar 26, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
3.30
P/C
3.21
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
16.78
Current Ratio
16.78
Debt/Eq
0.01
LT Debt/Eq
0.01
Option/Short
Yes / Yes
EPS (ttm)
-1.20
EPS next Y
-1.55
EPS next Q
-0.40
EPS this Y
-8.89%
EPS next Y
-16.95%
EPS next 5Y
-15.32%
EPS past 3/5Y
-2.32% -52.23%
Sales past 3/5Y
- -
EPS Y/Y TTM
-1.42%
Sales Y/Y TTM
-
EPS Q/Q
-7.88%
Sales Q/Q
-
Insider Own
44.74%
Insider Trans
0.00%
Inst Own
62.88%
Inst Trans
24.91%
ROA
-34.57%
ROE
-36.87%
ROIC
-36.31%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-0.88%
SMA50
-10.42%
SMA200
-14.08%
Trades
Shs Outstand
63.79M
Shs Float
35.38M
52W High
17.25 -39.30%
52W Low
6.81 53.74%
Volatility
5.63% 5.84%
ATR (14)
0.64
RSI (14)
45.37
Beta
1.75
Rel Volume
0.00
Avg Volume
577.17K
Volume
0
Perf Week
2.55%
Perf Month
-0.10%
Perf Quarter
-30.66%
Perf Half Y
-27.14%
Perf YTD
11.62%
Perf Year
48.30%
Perf 3Y
410.73%
Perf 5Y
-47.68%
Perf 10Y
-
Prev Close
10.47
Price
10.47
Change %
0.00%
Consensus
Strong Buy
Avg. Price Target
$21.57
Implied Upside
+106.0%
Analysts12incl. previous ratings
Rating Distribution9 Buy · 3 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 02, 2026Initiated
WFC logoWWells Fargo
Overweight$26+148.3%
May 12, 2026Initiated
CCantor Fitzgerald
Overweight
Mar 16, 2026Initiated
JEF logoJJefferies
Buy$15+43.3%
Jan 07, 2026Initiated
OPY logoOOppenheimer
Outperform$18+71.9%
Dec 03, 2025Upgrade
LLeerink Partners
Market Perform → Outperform$14+33.7%
Dec 03, 2025Initiated
CCraig Hallum
Buy$15+43.3%
Nov 20, 2025Upgrade
RY logoRRBC Capital Mkts
Sector Perform → Outperform$13+24.2%
May 07, 2024Upgrade
PPiper Sandler
Neutral → Overweight$6 → $12+14.6%
Nov 14, 2023Downgrade
PPiper Sandler
Overweight → Neutral$42 → $6-42.7%
Aug 15, 2023Downgrade
WWedbush
Outperform → Neutral$19 → $6-42.7%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Logos Global Master Fund LPDirectorNov 18 '25Proposed Sale7.43120,000891,600Nov 18 04:28 PM
Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. It is created to design, develop and commercialize a novel class of small molecule therapeutic candidates (GeneTACs) designed to directly address the underlying basis of genetic disease. The company was founded by Pratik Shah and Aseem Z. Ansari on December 18, 2017 and is headquartered in Carlsbad, CA.
Co-FounderMr. Pratik Shah Ph.D.
Chief Operating OfficerDr. Sean Jeffries Ph.D.
Chief Medical OfficerDr. Chris M. Storgard M.D.
Co-Founder & Scientific AdvisorDr. Aseem Z. Ansari Ph.D.
Chief Accounting OfficerMs. Julie D. Burgess CPA